Results 271 to 280 of about 178,517 (322)

Bruton’s Tyrosine Kinase in Ankylosing Spondylitis

Spine, 2023
Study Design. Prospective case-control study. Objective. To explore the role of Bruton’s tyrosine kinase (BTK) in ankylosing spondylitis (AS). Summary of Background Data.
Hsien-Tzung, Liao, Chun-Hsiung, Chen
openaire   +2 more sources

Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).

Journal of Medicinal Chemistry, 2022
Bruton's tyrosine kinase (BTK), a Tec family tyrosine kinase, is critical in immune pathways as an essential intracellular signaling element, participating in both adaptive and immune responses. Currently approved BTK inhibitors are irreversible covalent
T. D. Owens, K. Brameld, E. Verner, T. Ton, Xiaoyan Li, Jiang Zhu, M. Masjedizadeh, J. M. Bradshaw, R. Hill, D. Tam, A. Bisconte, Eun Ok Kim, M. Francesco, Y. Xing, J. Shu, D. Karr, Jacob LaStant, D. Finkle, Natalie Loewenstein, H. Haberstock-Debić, Michael J. Taylor, P. Nunn, C. Langrish, D. Goldstein   +23 more
semanticscholar   +1 more source

Role of Bruton's tyrosine kinase in immunodeficiency

Current Opinion in Immunology, 1994
The genetic defect associated with human X-linked agammaglobulinemia and murine X-linked immunodeficiency was recently shown to result from lack of function of a new cytoplasmic tyrosine kinase, called Bruton's tyrosine kinase (Btk). The phenotypes associated with these immunodeficiencies indicate that Btk plays a critical role in B-lymphocyte ...
David J. Rawlings, Owen N. Witte, Satoshi Tsukada   +2 more
openaire   +3 more sources

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Journal of Medicinal Chemistry, 2019
Aberrant activation of Bruton's tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas suggesting that inhibition of BTK is useful in the treatment of hematological malignancies.
Yunhang Guo, Ye Liu, N. Hu, D. Yu, Changyou Zhou, G. Shi, Bo Zhang, Min Wei, Jun-hua Liu, L. Luo, Zhiyu Tang, Huipeng Song, Yin Guo, X. Liu, D. Su, Shuo Zhang, Xiaomin Song, Xing Zhou, Yuan Hong, Shuaishuai Chen, Zhenzhen Cheng, S. Young, Q. Wei, Haisheng Wang, Qiuwen Wang, Lei Lv, Fan Wang, Haipeng Xu, Hanzi Sun, Haimei Xing, Na Li, Wei Zhang, Zhongbo Wang, Guodong Liu, Zhijian Sun, Dongping Zhou, Wei Li, Libin Liu, Lai Wang, Zhiwei Wang   +39 more
semanticscholar   +1 more source

Signalling of Bruton's Tyrosine Kinase, Btk

Scandinavian Journal of Immunology, 1999
Bruton's tyrosine kinase, which is encoded by the BTK gene, is a cytoplasmic protein tyrosine kinase (PTK) crucial for B‐cell development and differentiation. It belongs to the Tec family of PTKs containing several domains that are characteristic of signalling molecules.
C. I. E. Smith, Birger Christensson, Beston F. Nore, Abdalla J. Mohamed   +3 more
openaire   +3 more sources

Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.

Journal of Medicinal Chemistry, 2022
Bruton's tyrosine kinase proteolysis-targeting chimeras (BTK-PROTACs) have emerged as a promising approach to address the limitations of BTK inhibitors.
Jingyu Zhang, J. Che, Xiaomin Luo, Mingfei Wu, Wei-juan Kan, Yuheng Jin, Hanlin Wang, Ao Pang, Cong Li, Wenhai Huang, Shenxin Zeng, Weihao Zhuang, Yizhe Wu, Yongjin Xu, Yubo Zhou, Jia Li, Xiaowu Dong   +16 more
semanticscholar   +1 more source

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Journal of Medicinal Chemistry, 2020
Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases.
D. Angst, F. Gessier, P. Janser, A. Vulpetti, Rudolf Wälchli, C. Beerli, A. Littlewood-Evans, J. Dawson, B. Nuesslein‐Hildesheim, G. Wieczorek, S. Gutmann, C. Scheufler, A. Hinniger, A. Zimmerlin, Enrico G. Funhoff, R. Pulz, B. Cenni   +16 more
semanticscholar   +1 more source

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.

Journal of Medicinal Chemistry, 2018
Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, respectively.
J. Crawford, Adam R. Johnson, D. Misner, L. Belmont, G. Castanedo, R. Choy, Melis Coraggio, Liming Dong, C. Eigenbrot, R. Erickson, N. Ghilardi, Jonathan Hau, A. Katewa, P. B. Kohli, Wendy Lee, J. Lubach, Brent S. McKenzie, D. Ortwine, Leah K Schutt, Suzanne Tay, Binqing Wei, K. Reif, Lichuan Liu, H. Wong, W. Young   +24 more
semanticscholar   +1 more source

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.

Biochemistry, 2018
Inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies, yet >80% of CLL patients develop ...
A. Buhimschi, Haley Armstrong, M. Toure, S. Jaime-Figueroa, Timothy L Chen, A. Lehman, J. Woyach, A. Johnson, J. Byrd, C. Crews   +9 more
semanticscholar   +1 more source

Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.

Journal of Medicinal Chemistry, 2022
Despite significant efficacy, one of the major limitations of small-molecule Bruton's tyrosine kinase (BTK) agents is the presence of clinically acquired resistance, which remains a major clinical challenge.
Shan-liang Sun, Shih-han Wu, Jihui Kang, Yi-Yuan Ma, Lu Chen, P. Cao, Liang Chang, Ning Ding, Xin Xue, Nianyu Li, Zhi‐Hao Shi   +10 more
semanticscholar   +1 more source